The inauguration ceremony of the QbD Pharma preparation workshop was successfully held on September 9, 2025 in Cangzhou, Hebei, China

QbD Pharmaceutical's High-end Injection Base Grandly Completed, Paving the Way for New Development in Pharmaceutical Industry
On September 9, 2025, a grand completion ceremony of QbD Pharmaceutical's High-end Injection Base was held in Cangzhou Economic Development Zone, marking a crucial milestone in the company's development and injecting new vitality into China's biopharmaceutical industry.
The ceremony attracted elites from various fields including government, industry, academia, research and medical sectors. Representatives from industry associations, senior executives of well-known pharmaceutical enterprises, experts from research institutions and universities, as well as mainstream media reporters were also present to witness this important moment, reflecting the widespread attention and strong support for QbD Pharmaceutical and its high-end injection base project.
With a huge total investment and a large area, QbD Pharmaceutical's High-end Injection Base has been constructed in strict accordance with international advanced standards since its launch. Now, this modern pharmaceutical production and R&D base stands tall, showcasing remarkable strength. Inside the base, first-class production equipment is everywhere. The ultra-precise liquid preparation system ensures uniform composition and accurate proportion of each drop of liquid medicine through precise automatic control, laying a solid foundation for drug quality from the source. The high-speed filling equipment achieves efficient and stable filling operations with micron-level filling accuracy, greatly improving production efficiency. The new-generation moist heat sterilization equipment builds a strong defense line for drug safety with its strong penetrability and precise temperature control technology. In addition, high-precision bottle washing machines conduct in-depth cleaning of packaging containers using all-round spraying and ultrasonic cleaning technology to ensure no impurity residues; intelligent capping machines complete capping and sealing accurately at a millisecond-level response speed, ensuring the tightness of drugs during storage and transportation; high-sensitivity leak detectors can accurately identify extremely small packaging leaks using advanced vacuum detection technology, guaranteeing the quality of each injection.
Moreover, the base is equipped with a strict quality management system and a strong R&D team. Adhering to the fundamental concept of "Quality by Design (QbD)" and following international pharmaceutical quality management standards, QbD Pharmaceutical is committed to providing safe and effective high-quality drugs for global patients. The R&D team, composed of many industry elites, continuously explores and innovates, injecting a steady stream of impetus into the company's product R&D.
QbD Pharmaceutical has always persisted in taking innovation as the core driving force and actively established long-term and stable industry-university-research cooperation relationships with well-known research institutions and universities such as the School of Pharmacy of Hebei Medical University. Through close collaboration between both parties in drug R&D and technological innovation, a series of remarkable scientific research achievements have been made. The company's independently developed adrenaline auto-injection pen project was successfully approved as a 2023 Central Government-guided Local Science and Technology Development Fund Project, which is also the only pharmaceutical project in Cangzhou City selected for this fund. With prominent features such as self-injection, easy operation and accurate dosage, this product will provide timely and effective treatment for patients in emergency situations such as anaphylactic shock, filling the gap in related fields in China.
At present, QbD Pharmaceutical has obtained a number of independent intellectual property rights, with many products in the clinical research stage and some products to be approved for marketing soon. The company's products focus on fields such as acute rescue drugs, contrast agents and anesthetics. Every year, more than 15 self-owned APIs (Active Pharmaceutical Ingredients) and over 20 preparations will be declared for marketing in a phased manner. Its product layout is based on scientific rigor: first, focusing on differentiated varieties between Europe, America and China; second, complying with the "small, new and special" principle, i.e., products with a certain market capacity and technical barriers in APIs or preparations; third, complex injections with technical accessibility.
The completion of the high-end injection base has laid a solid foundation for QbD Pharmaceutical's future development. In the future journey, the company will